Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer
2024 · Scientific Reports · 13 citations
https://doi.org/10.1038/s41598-023-48546-y
C
Cindy Jiang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
289
Citations
10
h-index
10
i10-index
Cindy Jiang is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Esophageal Cancer Research and Treatment. The author has an h-index of 10, co-authored 41 publications.
ORCID: 0000-0002-2459-1875Papers by this author
worksGenomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data
2024 · European Urology Oncology · 6 citations
https://doi.org/10.1016/j.euo.2024.12.006
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database
2026 · Clinical Genitourinary Cancer · 0 citations
https://doi.org/10.1016/j.clgc.2026.102501
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat